Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) shares dropped 2.2% during mid-day trading on Friday . The company traded as low as $11.45 and last traded at $11.45, with a volume of 158,845 shares trading hands. The stock had previously closed at $11.71.

MNTA has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 4th. Brean Capital reiterated a “buy” rating and set a $19.00 target price on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 4th. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 27th. Goldman Sachs Group Inc. initiated coverage on Momenta Pharmaceuticals in a research report on Monday, June 6th. They set a “neutral” rating and a $14.00 target price on the stock. Finally, Leerink Swann restated an “outperform” rating and issued a $18.00 price objective (down previously from $21.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, May 4th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $18.40.

The stock has a 50 day moving average price of $11.21 and a 200 day moving average price of $10.60. The firm’s market capitalization is $779.91 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its earnings results on Tuesday, May 3rd. The biotechnology company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by $0.03. The business earned $19.90 million during the quarter, compared to the consensus estimate of $28.12 million. The business’s quarterly revenue was up 132.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.40) EPS. On average, analysts predict that Momenta Pharmaceuticals Inc. will post ($1.33) earnings per share for the current fiscal year.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of the business’s stock in a transaction on Friday, May 20th. The stock was sold at an average price of $10.18, for a total transaction of $59,858.40. Following the sale, the president now directly owns 349,521 shares in the company, valued at $3,558,123.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Other hedge funds have recently bought and sold shares of the company. Morgan Stanley increased its stake in Momenta Pharmaceuticals by 123.0% in the fourth quarter. Morgan Stanley now owns 69,759 shares of the biotechnology company’s stock worth $1,035,000 after buying an additional 38,470 shares during the last quarter. Rhumbline Advisers increased its stake in Momenta Pharmaceuticals by 9.9% in the fourth quarter. Rhumbline Advisers now owns 75,638 shares of the biotechnology company’s stock worth $1,122,000 after buying an additional 6,835 shares during the last quarter. GSA Capital Partners LLP increased its stake in Momenta Pharmaceuticals by 298.9% in the fourth quarter. GSA Capital Partners LLP now owns 88,251 shares of the biotechnology company’s stock worth $1,310,000 after buying an additional 66,130 shares during the last quarter. Swiss National Bank increased its stake in Momenta Pharmaceuticals by 2.6% in the fourth quarter. Swiss National Bank now owns 91,500 shares of the biotechnology company’s stock worth $1,358,000 after buying an additional 2,300 shares during the last quarter. Finally, California State Teachers Retirement System increased its stake in Momenta Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 113,170 shares of the biotechnology company’s stock worth $1,679,000 after buying an additional 1,801 shares during the last quarter.

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.